- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | RenovoRx, Inc. - 10-K/A, Annual Report | 2 | SEC Filings | ||
| Do | RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| Do | RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| Do | RenovoRx GAAP EPS of -$0.09 misses by $0.01, revenue of $0.56M beats by $0.1M | 2 | Seeking Alpha | ||
| Do | RenovoRx, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| Do | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.04. | RenovoRx, Inc.: Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 08.04. | RenovoRx, Inc.: RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum | 1 | GlobeNewswire (USA) | ||
| 01.04. | RenovoRx, Inc.: RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | 1 | GlobeNewswire (USA) | ||
| 31.03. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | RenovoRx GAAP EPS of -$0.32 in-line, revenue of $1.12M misses by $0.18M | 1 | Seeking Alpha | ||
| 30.03. | RenovoRx, Inc.: RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update | 559 | GlobeNewswire (Europe) | RenovoCath- Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated... ► Artikel lesen | |
| 27.03. | RenovoRx ernennt Dr. Ramtin Agah zum Executive Chairman und passt Vergütung an | 3 | Investing.com Deutsch | ||
| 26.03. | RenovoRx surpasses 100 patients in Phase III pancreatic trial | 7 | Investing.com | ||
| 23.03. | RenovoRx, Inc.: RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement | 3 | GlobeNewswire (USA) | ||
| 23.03. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | RenovoRx announces $10 million private placement | 1 | Seeking Alpha | ||
| 18.03. | RenovoRx sichert sich 10 Mio. US-Dollar durch überzeichnete Privatplatzierung | 2 | Investing.com Deutsch |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,40 | -2,98 % | BioNTech-Krise vs. Emyria-Durchbruch? Warum Daten jetzt die Forschung schlagen | ||
| MODERNA | 42,000 | -0,52 % | Moderna-Aktie steigt weiter: Hantavirus im Fokus | Die Sorge rund um das Hantavirus wächst: Auf dem Kreuzfahrtschiff "Hondius" wurden mehrere Infektionen mit der seltenen südamerikanischen Andes-Variante registriert, drei Personen starben. Trotz des... ► Artikel lesen | |
| BIOGEN | 165,76 | -0,16 % | Biogen Inc.: Biogen Completes Acquisition of Apellis Pharmaceuticals | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS). Apellis... ► Artikel lesen | |
| ILLUMINA | 121,00 | -1,37 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| CRISPR THERAPEUTICS | 41,750 | +0,19 % | 1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? | ||
| SANGAMO THERAPEUTICS | 0,126 | 0,00 % | XFRA GBY: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSANGAMO THERAP.INC.DL-... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,400 | +1,15 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| TEMPUS AI | 37,820 | +0,11 % | Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts | ||
| ATAIBECKLEY | 3,400 | -1,73 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| RECURSION PHARMACEUTICALS | 2,920 | -0,34 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| TWIST BIOSCIENCE | 42,610 | +0,66 % | Cathie Wood's ARK sells Twist Bioscience, buys Natera stock | ||
| OCULAR THERAPEUTIX | 7,850 | -0,63 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOXCEL THERAPEUTICS | 1,005 | +1,93 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 1,210 | +4,31 % | PDS Biotechnology Corporation: PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update | Investor Webcast Scheduled for 8:00 am ET PRINCETON, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,208 | 0,00 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,01 % bei einem Aktienkurs von 0,820 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.